

# Bijlage Zoekverantwoording

## Onderzoeksvraag 1 (module Preventie van hypercalciëmie)

Wat is het effect van behandeling met bisfosfonaten of denosumab op preventie van hypercalciëmie bij patiënten met multipel myeloom of botmetastasen?

### PICO

P	Patiënten met multipel myeloom of botmetastasen zonder hypercalciëmie
I	Bisfosfonaten of denosumab
C	Geen interventie, placebo, of een andere interventie
O	Cruciaal: percentage hypercalciëmie

### Zoekstrategie

Ovid MEDLINE(R): 1946 to December 27, 2022

- 1 exp MULTIPLE MYELOMA/ (46732)
- 2 myelom\$.mp. (82283)
- 3 exp PLASMACYTOMA/ (8833)
- 4 plasm?cytom\$.mp. (11187)
- 5 plasmoytom\$.mp. (389)
- 6 plasm\$ cell myelom\$.mp. (790)
- 7 myelomatosis.mp. (758)
- 8 LEUKEMIA, PLASMA CELL/ (1071)
- 9 (plasma\$ adj3 neoplas\$).mp. (2520)
- 10 kahler.mp. (254)
- 11 or/1-10 (90637)
- 12 exp Bone Neoplasms/sc (27617)
- 13 exp Neoplasm Metastasis/ (221659)
- 14 exp "Bone and Bones"/ (665516)
- 15 13 and 14 (3990)
- 16 (bone\$ adj10 metasta\$).mp. (30241)
- 17 12 or 15 or 16 (46936)
- 18 11 or 17 (136035)
- 19 exp Diphosphonates/ (27908)
- 20 biphosphonate\$.mp. (507)
- 21 bisphosphanate\$.mp. (15)
- 22 diphosphonate\$.mp. (20395)
- 23 diphosphanate\$.mp. (10)
- 24 exp Etidronic Acid/ (2785)
- 25 etidronate\$.mp. (1290)
- 26 exp Clodronic Acid/ (1719)
- 27 clodronate\$.mp. (2222)
- 28 pamidronate\$.mp. (3008)
- 29 exp Alendronate/ (3988)
- 30 alendronate.mp. (5370)
- 31 risedronate\$.mp. (1636)
- 32 tiludronate\$.mp. (142)
- 33 ibandronate\$.mp. (964)
- 34 zoledronate\$.mp. (1335)
- 35 incadronate\$.mp. (75)
- 36 olpadronate\$.mp. (57)
- 37 neridronate\$.mp. (104)
- 38 RANK Ligand/ (8561)
- 39 RANK ligand.mp. (8879)
- 40 RANK ligand inhibitor\$.mp. (47)

41 denosumab.mp. (3286)  
 42 prolia.mp. (49)  
 43 Xgeva.mp. (17)  
 44 exp Denosumab/ (2225)  
 45 or/19-44 (41521)  
 46 18 and 45 (6464)  
 47 randomized controlled trial.pt. (581950)  
 48 controlled clinical trial.pt. (95108)  
 49 randomized.ab. (513566)  
 50 placebo.ab. (214932)  
 51 clinical trials as topic.sh. (201502)  
 52 randomly.ab. (337367)  
 53 trial.ti. (242253)  
 54 47 or 48 or 49 or 50 or 51 or 52 or 53 (1347657)  
 55 exp animals/ not humans.sh. (5083790)  
 56 54 not 55 (1228519)  
 57 meta-analysis.mp.pt. or review.pt. or search:.tw. (3172194)  
 58 56 or 57 (4187278)  
 59 46 and 58 (2257)

Ovid MEDLINE(R) Epub Ahead of Print <December 27, 2022>, Ovid MEDLINE(R) Daily Update <December 27, 2022>

1 exp MULTIPLE MYELOMA/ (67)  
 2 myelom\$.mp. (783)  
 3 exp PLASMACYTOMA/ (2)  
 4 plasm?cytom\$.mp. (54)  
 5 plasmozytom\$.mp. (0)  
 6 plasm\$ cell myelom\$.mp. (11)  
 7 myelomatosis.mp. (0)  
 8 LEUKEMIA, PLASMA CELL/ (0)  
 9 (plasma\$ adj3 neoplas\$).mp. (37)  
 10 kahler.mp. (3)  
 11 or/1-10 (825)  
 12 exp Bone Neoplasms/sc (11)  
 13 exp Neoplasm Metastasis/ (79)  
 14 exp "Bone and Bones"/ (579)  
 15 13 and 14 (0)  
 16 (bone\$ adj10 metasta\$).mp. (346)  
 17 12 or 15 or 16 (352)  
 18 11 or 17 (1162)  
 19 exp Diphosphonates/ (23)  
 20 biphosphonate\$.mp. (1)  
 21 bisphosphanate\$.mp. (0)  
 22 diphosphonate\$.mp. (51)  
 23 diphosphanate\$.mp. (0)  
 24 exp Etidronic Acid/ (0)  
 25 etidronate\$.mp. (6)  
 26 exp Clodronic Acid/ (1)  
 27 clodronate\$.mp. (15)  
 28 pamidronate\$.mp. (26)  
 29 exp Alendronate/ (1)  
 30 alendronate.mp. (42)  
 31 risedronate\$.mp. (9)  
 32 tiludronate\$.mp. (1)  
 33 ibandronate\$.mp. (5)

- 34 zoledronate\$.mp. (27)
- 35 incadronate\$.mp. (0)
- 36 olpadronate\$.mp. (0)
- 37 neridronate\$.mp. (0)
- 38 RANK Ligand/ (5)
- 39 RANK ligand.mp. (17)
- 40 RANK ligand inhibitor\$.mp. (1)
- 41 denosumab.mp. (107)
- 42 prolia.mp. (4)
- 43 Xgeva.mp. (3)
- 44 exp Denosumab/ (5)
- 45 or/19-44 (263)
- 46 18 and 45 (43)
- 47 randomized controlled trial.pt. (994)
- 48 controlled clinical trial.pt. (16)
- 49 randomized.ab. (10256)
- 50 placebo.ab. (2672)
- 51 clinical trials as topic.sh. (62)
- 52 randomly.ab. (5247)
- 53 trial.ti. (5137)
- 54 47 or 48 or 49 or 50 or 51 or 52 or 53 (17489)
- 55 exp animals/ not humans.sh. (4124)
- 56 54 not 55 (17300)
- 57 meta-analysis.mp,pt. or review.pt. or search:.tw. (62904)
- 58 56 or 57 (76292)
- 59 46 and 58 (25)

#### Embase

#1.	'malignant plasmacytoma'/exp	108006
#2.	'plasma cell leukemia'/exp	2256
#3.	myelom*:ti,ab	115766
#4.	plasm?cytom*:ti,ab	10562
#5.	plasmozytom*:ti,ab	20
#6.	(plasm* NEAR/1 cell NEAR/1 myelom*):ti,ab	1443
#7.	myelomatosis:ti,ab	833
#8.	(plasma* NEAR/3 neoplas*):ti,ab	4025
#9.	kahler:ti,ab	384
#10.	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9	150765
#11.	'bone metastasis'/exp	53188
#12.	(bone* NEAR/10 metasta*):ti,ab	56456
#13.	#10 OR #11 OR #12	226367

#14.	'bisphosphonic acid derivative'/exp	75381
#15.	biphosphonate*:ti,ab	1046
#16.	bisphosphanate*:ti,ab	47
#17.	diphosphonate*:ti,ab	4601
#18.	diphosphanate*:ti,ab	20
#19.	etidronate*:ti,ab	1604
#20.	clodronate*:ti,ab	3530
#21.	pamidronate*:ti,ab	3894
#22.	alendronate*:ti,ab	8026
#23.	risedronate*:ti,ab	3007
#24.	tiludronate*:ti,ab	187
#25.	ibandronate*:ti,ab	1991
#26.	zoledronate*:ti,ab	2459
#27.	incadronate*:ti,ab	90
#28.	olpadronate*:ti,ab	75
#29.	neridronate*:ti,ab	189
#30.	'osteoclast differentiation factor'/exp	22315
#31.	(rank NEAR/1 ligand):ti,ab	1604
#32.	denosumab:ti,ab	7094
#33.	prolia:ti,ab	126
#34.	xgeva:ti,ab	64
#35.	'denosumab'/exp	11986
#36.	#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35	103053
#37.	#13 AND #36	16389
#38.	#13 AND #36 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) AND ([article]/lim OR [article in press]/lim OR [review]/lim) AND ([dutch]/lim OR [english]/lim) AND ([embase]/lim OR [pubmed-not-medline]/lim)	751

### Cochrane Library

#1 MeSH descriptor: [Multiple Myeloma] explode all trees 1811

#2 myelom\*:ti,ab 6329  
 #3 MeSH descriptor: [Plasmacytoma] explode all trees 89  
 #4 plasm?cytom\*:ti,ab 117  
 #5 plasmoytom\*:ti,ab 1  
 #6 (plasm\* NEAR/1 cell NEAR/1 myelom\*):ti,ab 24  
 #7 myelomatosis:ti,ab 34  
 #8 MeSH descriptor: [Leukemia, Plasma Cell] explode all trees 3  
 #9 (plasma\* NEAR/3 neoplas\*):ti,ab 57  
 #10 kahler:ti,ab 21  
 #11 {or #1-#10} 6545  
 #12 MeSH descriptor: [Bone Neoplasms] explode all trees 1319  
 #13 MeSH descriptor: [Neoplasm Metastasis] explode all trees 5515  
 #14 MeSH descriptor: [Bone and Bones] explode all trees 14200  
 #15 #13 and #14 18  
 #16 (bone\* NEAR/10 metasta\*):ti,ab 3165  
 #17 #11 or #12 or #15 or #16 10313  
 #18 MeSH descriptor: [Diphosphonates] explode all trees 2698  
 #19 (biphosph?nate\* or bisphosph?nate\* or diphosph?nate\*):ti,ab 2655  
 #20 MeSH descriptor: [Etidronic Acid] explode all trees 477  
 #21 MeSH descriptor: [Clodronic Acid] explode all trees 192  
 #22 MeSH descriptor: [Alendronate] explode all trees 780  
 #23 (etidronate\* or clodronate\* or pamidronate\* or alendronate\* or risedronate\* or tiludronate\* or ibandronate\* or zoledronate\* or incadronate\* or olpadronate\* or neridronate\*):ti,ab 3805  
 #24 MeSH descriptor: [RANK Ligand] explode all trees 135  
 #25 (RANK NEAR/1 ligand\*):ti,ab 85  
 #26 MeSH descriptor: [Denosumab] explode all trees 406  
 #27 denosumab:ti,ab 1174  
 #28 prolia:ti,ab 80  
 #29 Xgeva:ti,ab 34  
 #30 {or #18-#29} 6537  
 #31 #17 and #30 1181

Tabel 8. Resultaten van zoekactie van onderzoeksvraag 1

Database	Aantal
Medline	4 2257
PreMedline	6 25
Embase	8 751
CDSR	10 10
CENTRAL	2 1169
<b>Totaal aantal resultaten</b>	<b>4 4212</b>
Aantal geëxcludeerd (dubbelen en foute taal)	6 1222
<b>Totaal aantal unieke resultaten</b>	<b>8 2990</b>

Tabel 9. Overzicht van geëxcludeerde studies gebaseerd op beoordeling van de volledige tekst van onderzoeksvraag 1

Referentie	Reden voor exclusie
Abildgaard, N., et al., Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. European Journal of Haematology, 1998. 61(2): p. 128-34.	Substudie van Brincker 1998

Adami, S. and M. Mian, Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. <i>Recent Results in Cancer Research</i> , 1989. 116: p. 67-72.	Narrative review
Aft, R.L., et al., Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. <i>British Journal of Cancer</i> , 2012. 107(1): p. 7-11.	Geen botmetastasen, geen SREs gerapporteerd
Al Farii, H., et al., Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials. <i>JAAOS: Global Research and Reviews</i> , 2020. 4(8): p. e20.00045.	Hypercalciëmie niet gerapporteerd, enkel pathologische fracturen
Al Farii, H., et al., Zoledronic Acid Versus Denosumab for Prevention of Spinal Cord Compression in Advanced Cancers With Spine Metastasis: A Meta-Analysis of Randomized Controlled Trials. <i>Global Spine Journal</i> , 2020. 10(6): p. 784-789.	Uitkomst is 'spinal cord compression'
Alegre, A., et al., Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. <i>European Journal of Haematology</i> , 2014. 92(3): p. 181-8.	Narrative review
Alibhai, S.M.H., et al., Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline. <i>Clinical Oncology (Royal College of Radiologists)</i> , 2017. 29(6): p. 348-355.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Amir, E., et al. Pilot Randomized Trial of De-Escalated (q12 Weekly) Versus Standard (q3-4 Weekly) Intravenous Bisphosphonates in Women with Low-Risk Bone Metastases from Breast Cancer 55. <i>Cancer research</i> , 2011. 71, Abstract no: P4-16-08.	Abstract
Amir, E., et al., Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. <i>American Journal of Clinical Oncology</i> , 2013. 36(5): p. 436-42.	Hypercalciëmie niet gerapporteerd, wel SREs; vergelijking van verschillende intervallen van toediening
Anderson, K., et al., Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018. 36(8): p. 812-818.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Anonymous A randomized, double-blind, multicenter, comparative trial of i.v. zoledronate (4 mg or 8 mg) versus i.v. Aredia (90 mg), as an adjunct to standard therapies, in the treatment of multiple myeloma and breast cancer patients with cancer-related bone lesions. <i>Pharmaceutical industry clinical trials database</i> , 2003.	Trial protocol
Anonymous, Canadian Agency for Drugs and Technologies in Health. <i>CADTH Common Drug Reviews</i> , 2016. 11: p. 11.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Apsangikar, P., et al. Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology. <i>Asian journal of oncology</i> , 2022. DOI: 10.1055/s-0042-1744505.	Evaluatie van biosimilar denosumab
Arican, A., et al., The effect of two different doses of oral clodronate on pain in patients with bone metastases. <i>Medical Oncology</i> , 1999. 16(3): p. 204-10.	Serum Ca, geen %
Attal, M., et al., Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. <i>Blood</i> , 2006. 108(10): p. 3289-94.	Hypercalciëmie niet gerapporteerd, wel skeletal events en toxicity

Attardo-Parrinello, G., et al., Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. Archives of Internal Medicine, 1987. 147(9): p. 1629-33.	Geen RCT
Ausili-Cefaro, G., et al. Radiation therapy vs radiation therapy + pamidronate (Aredia) in elderly patients with breast cancer and lytic bone metastases: a GROG-GIOGer randomized clinical trial. Rays - international journal of radiological sciences, 1999. 24, 49-52.	Geen full-text
Aviles, A., et al., Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Medical Oncology, 2007. 24(2): p. 227-30.	Hypercalciëmie niet gerapporteerd, wel skeletal events en toxicity
Aviles, A., et al., Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients. Clinical lymphoma, myeloma & leukemia, 2017. 17(4): p. 207-210.	Hypercalciëmie niet gerapporteerd, wel skeletal events en toxicity
Avilés, A., et al., Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Current Oncology, 2013. 20(1): p. e13-e20.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Barrett-Lee, P., et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial-first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer research, 2012. 72, DOI: 10.1158/0008-5472.SABCS12-PD07-09.	Abstract
Belch, A., et al. A controlled trial of daily etidronate disodium (Didronel) in the management of bone disease of multiple myeloma. Blood, 1988. 72, 238a.	Geen full-text
Bell, R., R. Coleman, and B. Bergstrom Improving clinical outcomes and treatment convenience with oral ibandronate for metastatic bone disease. 2003.	Abstract
Bell, R.B.J.-J.B.B. Renal safety of intravenous ibandronate for up to 4 years in patients with breast cancer and bone metastases. 2004.	Abstract
Beltrán, M., et al. Phase III randomized and comparative study of pamidronate disodium in patients with breast cancer and bone metastases to assess time to bone disease progression. Oncología. V congreso de la SEOM y x de la SAC, 1995. 18, 75.	Abstract
Beltrán, M., et al. Randomized, phase III comparative trial in patients with breast cancer and bone metastases with i.v. pamidronate disodium (APD), to evaluate the time to progression of bone disease. Oncología (barcelona), 1995. 18, 75.	Abstract
Berenson, J.R., et al., American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology, 2002. 20(17): p. 3719-36.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Berenson, J.R., et al., Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial). The Journal of Supportive Oncology, 2011. 9(1): p. 32-40.	Geen full-text
Berry, S., et al., The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Canadian Journal of Urology, 2006. 13(4): p. 3180-8.	Hypercalciëmie niet gerapporteerd
Bhowmick, R., et al. Pain control and improvement in quality of life with intravenous zoledronic acid versus oral ibandronate in management of painful bone metastasis receiving palliative radiotherapy: a prospective randomized study. Journal of cancer research and therapeutics, 2016. 12, S78-.	Abstract

Bink, K.F., Analysis of denosumab on skeletal-related events in patients with advanced breast cancer. <i>Clinical Journal of Oncology Nursing</i> , 2015. 19(5): p. E108-14.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Bloomfield, D.J., Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. <i>Journal of Clinical Oncology</i> , 1998. 16(3): p. 1218-25.	Geen kwaliteitsbeoordeling van geïnccludeerde studies, enkel gezocht in Medline
Body, J.-J., et al. Denosumab for the prevention of symptomatic skeletal events (SSEs) in patients with bone-metastatic breast cancer: a comparison with skeletal-related events (SREs). <i>Annals of oncology</i> , 2016. 27, DOI: 10.1093/annonc/mdw390.31.	Abstract
Body, J.-J., et al. Hypocalcemia in patients with metastatic bone disease receiving denosumab. <i>Journal of clinical oncology</i> , 2013. 31.	Abstract
Body, J.-J., et al. Intravenous and oral ibandronate reduces the risk of skeletal related events in metastatic bone disease from breast cancer. 2003.	Abstract
Body, J., et al. Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone. <i>Proceedings of the american society of clinical oncology</i> , 1999. 18, 575a, Abstract 2222.	Abstract
Body, J., et al. Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid of markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial. <i>Journal of clinical oncology</i> , 2005. 23, 12s.	Abstract
Body, J.J., et al., A study of the biological receptor activator of nuclear factor- $\kappa$ ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. <i>Clinical Cancer Research</i> , 2006. 12(4): p. 1221-1228.	Effect op hypercalciëmie wordt slechts narratief gerapporteerd
Body, J.J., et al., Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. <i>Journal of Bone &amp; Mineral Research</i> , 2010. 25(3): p. 440-6.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Body, J.J., et al., Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion. <i>BMC Urology</i> , 2018. 18(1): p. 81.	Narrative review
Body, J.J., et al., Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. <i>Annals of Oncology</i> , 2003. 14(9): p. 1399-405.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Body, J.J., et al., Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. <i>Journal of Bone &amp; Mineral Research</i> , 1995. 10(8): p. 1191-6.	Geen RCT
Body, J.J., et al., Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. <i>Pain</i> , 2004. 111(3): p. 306-312.	Hypercalciëmie niet gerapporteerd, wel QOL en safety
Body, J.J., et al., Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. <i>Annals of Oncology</i> , 2007. 18(7): p. 1165-71.	Serum Ca, geen %
Body, J.J., et al., Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. <i>British Journal of Cancer</i> , 2004. 90(6): p. 1133-1137.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity



Body, J.J., Reducing skeletal complications and bone pain with intravenous ibandronate for metastatic bone disease. <i>European Journal of Cancer, Supplement</i> , 2004. 2(5): p. 5-8.	Beschrijving van 3 RCTs
Boyd, K., et al. Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results. <i>Journal of clinical oncology</i> , 2011. 29.	Abstract
Bozzo, A., et al., Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis. <i>Clinical Orthopaedics &amp; Related Research</i> , 2021. 479(9): p. 2047-2057.	Hypercalciëmie niet gerapporteerd, wel SREs
Brincker, H., et al., Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. <i>British Journal of Haematology</i> , 1998. 101(2): p. 280-6.	Sommige patiënten met hyperCa bij inclusie
Broom, R., et al. RAD001 and zoledronic acid in patients with renal cell carcinoma with bone metastases (RAZOR): a randomized phase II trial. <i>Journal of clinical oncology</i> , 2013. 31.	Abstract
Broom, R.J., et al., Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: A randomized first-line phase II trial. <i>Clinical Genitourinary Cancer</i> , 2015. 13(1): p. 50-58.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Brown, J.E., et al., The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. <i>Calcified Tissue International</i> , 2007. 81(5): p. 341-51.	Geen SREs gerapporteerd
Campbell-Baird, C., et al. Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: results from a randomized, controlled phase II study in patients with breast cancer and bone metastases. <i>Community oncology</i> , 2010. 7, 85-89.	Geen full-text
Cao, L., et al., Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis. <i>Oncotarget</i> , 2017. 8(52): p. 90308-90314.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity; vergelijking van verschillende intervallen van toediening
Carteni, G., et al., Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. <i>Oncologist</i> , 2006. 11(7): p. 841-8.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Cascinu, S., et al., Different doses of pamidronate in patients with painful osteolytic bone metastases. <i>Supportive Care in Cancer</i> , 1998. 6(2): p. 139-43.	Hypercalciëmie niet gerapporteerd, eerder weinig over safety; vergelijking van verschillende dosissen
Cassinello Espinosa, J., et al., SEOM guidelines for the treatment of bone metastases from solid tumours. <i>Clinical &amp; Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies &amp; of the National Cancer Institute of Mexico</i> , 2012. 14(7): p. 505-11.	Geen systematisch literatuurnazicht
Chantraine, A., et al. Dichloromethylene diphosphonate in the treatment of lytic bone metastases. <i>Presse medicale (Paris, France : 1983)</i> , 1984. 13, 479-482.	Geen full-text
Chapuy, M.C., et al., Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. <i>Journal of Clinical Investigation</i> , 1980. 65(5): p. 1243-7.	Behandeling van hypercalciëmie, geen preventie

Chatziravdeli, V., et al., A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2022. 22(4): p. 596-621.	Hypercalciëmie niet gerapporteerd
Chen, C., et al., Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials. <i>Clinical Therapeutics</i> , 2020. 42(8): p. 1494-1507.e1.	Hypercalciëmie niet gerapporteerd
Chen, C., et al., Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and metaanalysis of randomized control trials. <i>PLoS ONE</i> , 2022. 17(9 September).	Hypercalciëmie niet gerapporteerd
Chen, F. and F. Pu, Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials. <i>Oncology Research and Treatment</i> , 2016. 39(7-8): p. 453-9.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Chen, J., et al., Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis. <i>International Journal of Clinical Pharmacy</i> , 2021. 43(1): p. 2-10.	Hypercalciëmie niet gerapporteerd
Chen, P., et al., Efficacy and safety of 188Re-HEDP in lung cancer patients with bone metastases: a randomized, multicenter, multiple-dose phase IIa study. <i>International Journal of Clinical Oncology</i> , 2021. 26(7): p. 1212-1220.	Interventie niet relevant voor PICO
Cheng, J., et al. Clinical analysis of therapeutic effect of zoledronic acid combined with radiotherapy for metastatic bone cancer. <i>Zhonghua zhong liu za zhi [Chinese journal of oncology]</i> , 2008. 30, 552-554.	Chinees
Cleeland, C., et al. Abstract P1-13-01: comparing the Effects of Denosumab and Zoledronic Acid on Pain Interference with Daily Functioning in a Randomized Phase 3 Trial of Patients with Breast Cancer and Bone Metastases. 2010. 70, DOI: 10.1158/0008-5472.SABCS10-P1-13-01.	Abstract
Cleeland, C.S., et al., Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. <i>Cancer</i> , 2013. 119(4): p. 832-8.	Focus op pijn als uitkomst
Clemens, M.R., K. Fessele, and M.E. Heim, Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. <i>Annals of Hematology</i> , 1993. 66(3): p. 141-6.	Sommige patiënten hadden hyperCa bij inclusie
Clemons, M., et al. A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases. <i>Annals of oncology</i> , 2019. 30, iii73- DOI: 10.1093/annonc/mdz118.002.	Abstract
Clemons, M., et al. A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer. <i>Journal of clinical oncology</i> , 2019. 37, DOI: 10.1200/JCO.2019.37.15_suppl.11501.	Abstract
Cleton, F., H.-V.A. van, and O. Bijvoet Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. <i>Recent results in cancer research</i> , 1989. 116, 73-78 DOI: 10.1007/978-3-642-83668-8_7.	Interim analyse van van Holten-Verzantvoort 1993
Coleman, R., et al. Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D-CARE study. <i>Journal of clinical oncology</i> , 2018. 36, DOI: 10.1200/JCO.2018.36.15-suppl.501.	Abstract
Coleman, R., et al. Double-blind randomized trial of pamidronate (AREDIA) for the palliative treatment of metastatic, bone disease. <i>Proc-annu-meet-am-soc-clin-oncol</i> , 1996. 15, Abs. A1706.	Abstract

Coleman, R., et al., Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer. <i>Advances in Therapy</i> , 2021. 38(8): p. 4569-4580.	Geen botmetastasen
Coleman, R.E., Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. <i>American Journal of Clinical Oncology</i> , 2002. 25(6 Suppl 1): p. S25-31.	Beschrijving van 3 RCTs
Coleman, R.E., et al., A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. <i>European Journal of Cancer</i> , 1998. 34(6): p. 820-4.	Hypercalciëmie niet gerapporteerd, wel safety
Coleman, R.E., et al., Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). <i>Journal of Bone Oncology</i> , 2018. 13: p. 123-135.	Geen botmetastasen
Coleman, R.E., et al., Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. <i>Annals of Oncology</i> , 1999. 10(3): p. 311-316.	Geen SREs gerapporteerd
Conte, P., et al. Delayed progression of bone metastases with bisphosphonate therapy: a randomized phase III trial with intravenous Aredia (pamidronate disodium) in breast cancer patients. <i>The breast</i> , 1993. 2, 202.	Abstract
Conte, P.F., et al., Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. <i>Journal of Clinical Oncology</i> , 1996. 14(9): p. 2552-2559.	Serum Ca, geen %
Conte, P.F., et al., Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. <i>Annals of Oncology</i> , 1994. 5 Suppl 7: p. S41-4.	Geen full-text
Cook, R.J., et al., Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. <i>Clinical Cancer Research</i> , 2006. 12(11 Pt 1): p. 3361-7.	Hypercalciëmie niet gerapporteerd
Cummins, O. Randomized Study of Single-Dose Local Radiotherapy Versus Ibandronate in Patients With Localized Metastatic Bone Pain. Physician data query (PDQ), 2004.	Geen full-text
D'Arena, G., et al., Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. <i>Leukemia &amp; Lymphoma</i> , 2011. 52(5): p. 771-5.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Daragon, A., et al. Etidronic acid in the treatment of multiple myeloma: results of a controlled study of etidronic acid versus placebo. TRAITEMENT DU MYELOME MULTIPLE PAR UN BIPHOSPHONATE: RESULTATS D'UNE ETUDE CONTROLEE DE L'ETIDRONATE CONTRE PLACEBO. <i>Revue de medecine interne / fondee ... par la Societe nationale francaise de medecine interne</i> , 1992. 13, S313.	Abstract
Daragon, A., et al., Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myelome (GERM). <i>European Journal of Medicine</i> , 1993. 2(8): p. 449-52.	Geen full-text
Davies, F., et al. Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial. <i>Journal of clinical oncology</i> , 2011. 29.	Abstract
De, B.R., et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). <i>Journal of oncology pharmacy practice</i> , 2012. 18, 22 DOI: 10.1177/1078155212439813.	Abstract
De, B.R., et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number-needed-to-treat (NNT) analysis. <i>Asia-</i>	Abstract

Pacific journal of clinical oncology, 2011. 7, 55-56 DOI: 10.1111/j.1743-7563.2011.01417.x.	
De, B.R., et al. Hypocalcaemia in patients with metastatic bone disease (MBD) receiving denosumab. Asia-Pacific journal of clinical oncology, 2013. 9, 117 DOI: 10.1111/ajco.12145.	Abstract
Dearnaley, D. and M. Sydes Preliminary evidence that an oral bisphosphonate can delay symptomatic progression of bone metastases from prostate cancer: first results of the MRC PR05 trial. British journal of cancer, 2001. 85, 1.	Abstract
Dearnaley, D. and M. Sydes Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 trial. Proceedings of the american society of clinical oncology, 2001. 20 (Pt 1), 174a, Abstract 693.	Abstract
Dearnaley, D.P., et al., A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). Journal of the National Cancer Institute, 2003. 95(17): p. 1300-1311.	Hypercalciëmie niet gerapporteerd, wel safety
Dearnaley, D.P., et al., Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncology, 2009. 10(9): p. 872-6.	Hypercalciëmie niet gerapporteerd
Dellis, A., et al., Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. Cancer Treatment Reviews, 2019. 73: p. 54-61.	Review van richtlijnen
Delmas, P., M. Chapuy, and E. Vignon Dichloromethylene diphosphonate (Clsub 2MDP) treatment of hypercalcaemia produced from bone metastases. Nouv-Press-Med, 1982. 11, 1471-1474.	Frans
Delmas, P.D., et al., Long-term effects of dichloromethylene diphosphonate (Cl2MDP) on skeletal lesions in multiple myeloma. Metabolic Bone Disease & Related Research, 1982. 4(3): p. 163-8.	Serum Ca, geen %
Dempster, D.W., et al., Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clinical Therapeutics, 2012. 34(3): p. 521-36.	Narrative review
Denham, J.W., et al., Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): An open-label, randomised, phase 3 factorial trial. The Lancet Oncology, 2014. 15(10): p. 1076-1089.	Geen botmetastasen
Diel, I., et al. Effect of 1-year intravenous ibandronate treatment on time to serum creatinine increase in patients with skeletal metastases from breast cancer. Annual meeting proceedings of the american society of clinical oncology, 2004. 59.	Abstract
Diel, I., et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European journal of cancer, 2011. 47, S237 DOI: 10.1016/S0959-8049%2811%2971124-8.	Abstract
Dimitroulis, I., et al. Comparative efficacy of ibandronic acid vs. Zoledronic acid in lung cancer patients with skeletal metastases. Do they alleviate the patient? Journal of thoracic oncology, 2014. 9, S203-s204.	Geen full-text
Dimitroulis, I., et al. Ibandronic acid vs. zoledronic acid in lung cancer patients with skeletal metastases. How do they compare? Journal of thoracic oncology, 2013. 8, S178 DOI: 10.1097/01.JTO.0000438438.14562.c8.	Abstract
Djulgovic, B., et al., Bisphosphonates in multiple myeloma. Cochrane Database of Systematic Reviews, 2001(4): p. CD003188.	Updated

Djulgovic, B., et al., Bisphosphonates in multiple myeloma. Cochrane Database of Systematic Reviews, 2002(3): p. CD003188.	Updated
Dong, M., et al. Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008. 30, 215-220.	Chinees
Double-blind randomised phase III multicentre trial comparing the effect of oral pamidronate (CGP 23339A - Aredia) with placebo in patients with newly diagnosed bone metastases from breast cancer (10924). European journal of cancer, 1994. 30, S38.	Abstract
Elomaa, I., et al., Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. International Urology & Nephrology, 1992. 24(2): p. 159-66.	Geen full-text
Ernst, D., et al. A double-blind, cross-over trial of IV clodronate in metastatic bone pain. Proc-annu-meet-am-soc-clin-oncol, 1990. 9, Abs. A307.	Abstract
Ernst, D., et al. Randomized, controlled trial of iv Clodronate in patients with painful bone metastases. Proc-annu-meet-am-soc-clin-oncol, 1993. 12, Abs. A1563.	Abstract
Ernst, D.S., et al., A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. Journal of Pain & Symptom Management, 1992. 7(1): p. 4-11.	Hypercalciëmie niet gerapporteerd
Ernst, D.S., et al., A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. Journal of Pain and Symptom Management, 1997. 13(6): p. 319-326.	Hypercalciëmie niet gerapporteerd
Ernst, D.S., et al., Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Journal of Clinical Oncology, 2003. 21(17): p. 3335-42.	Hypercalciëmie niet gerapporteerd, wel QOL en safety
Fallowfield, L., et al. Effect of denosumab versus zoledronic acid on health-related quality of life in patients with metastatic breast cancer. Journal of clinical oncology, 2011. 29.	Abstract
Fallowfield, L., et al. Health-related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive care in cancer, 2012. 20, S37 DOI: 10.1007/s00520-012-1479-7.	Abstract
Figg, W.D., et al., A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. Journal of Urology, 2005. 173(3): p. 790-6.	Hypercalciëmie niet gerapporteerd
Fizazi, K., et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. Journal of clinical oncology, 2010. 28, 951.	Abstract
Fizazi, K., et al. Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid. European urology, supplements, 2014. 13, e869-e869a.	Abstract
Fizazi, K., et al., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 2011. 377(9768): p. 813-22.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Fizazi, K., et al., Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology, 2009. 27(10): p. 1564-71.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Fontana, A., et al. Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma. Blood, 1998. 92, 106a.	Abstract

Ford, J.A., et al., Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. <i>European Journal of Cancer</i> , 2013. 49(2): p. 416-30.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Francini, F., et al., Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2011. 16(3): p. 264-9.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Francini, G., et al., Treatment of bone metastases with dichloromethylene bisphosphonate. <i>Journal of Clinical Oncology</i> , 1992. 10(4): p. 591-8.	Sommige patiënten hadden hyperCa bij inclusie
Fu, Q., et al. Phase II clinical trial of home-made incadronate in patients with pain of bone metastasis of malignancy or/and hypercalcemia. <i>Pharmaceutical care and research</i> , 2007. 7, 180-183.	Chinees
Fujiwara, Y., et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases. <i>Annals of oncology</i> , 2010. 21, ix12 DOI: 10.1093/annonc/mdq560.	Abstract
Fulfaro, F., et al., The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. <i>Pain</i> , 1998. 78(3): p. 157-169.	Narrative review
Gartrell, B.A., et al., Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. <i>European Urology</i> , 2015. 68(5): p. 850-8.	Narrative review
Geng, C.J., et al., Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials. <i>BMJ Open</i> , 2015. 5(6): p. e007258.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Gierloff, M., et al., Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial. <i>Clinical &amp; Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies &amp; of the National Cancer Institute of Mexico</i> , 2015. 17(6): p. 454-61.	Vergelijking niet relevant voor PICO
Gimsing, P., et al. Randomised Study on Prophylactic Pamidronate 30 mg vs. 90 mg in Multiple Myeloma (Nordic Myeloma Study Group). <i>Blood</i> , 2007. 110.	Abstract
Giordani, S., et al. A randomized study on 'prophylactic' use of disodium pamidronate in breast cancer patients (bcps) with bone metastasis at high risk (HR) of complication: the experience of an 'oncological hospital at home' (OHH). <i>Annals of oncology</i> , 1996. 7, 24.	Geen full-text
Glaspay, J. Phase II randomized study of AMG 162 versus bisphosphonates in patients with bone metastases secondary to advanced solid tumors or multiple myeloma. Physician data query (PDQ), 2005.	Geen full-text
Glennane, A., et al. An integrated analysis of denosumab versus zoledronic acid (ZA) for the prevention of skeletal-related events (sres) in patients with bone metastases (BMS) secondary to solid tumours. <i>Journal of oncology pharmacy practice</i> , 2012. 18, 21-22 DOI: 10.1177/1078155212439813.	Abstract
Gnant, M., et al. Long-term outcomes of adjuvant denosumab in breast cancer: fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebocontrolled ABCSG-18 trial. <i>Journal of clinical oncology</i> , 2022. 40, DOI: 10.1200/JCO.2022.40.16_suppl.507.	Abstract
Gnant, M., et al., Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial. <i>The Lancet</i> , 2015. 386(9992): p. 433-443.	Geen botmetastasen
Goldschmidt, H., et al. Meta analysis of published randomized trials on bisphosphonates in multiple myeloma. <i>The hematology journal</i> , 2001. 33.	Geen full-text

Gordon, D., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate in treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer. Proceedings of the american society of clinical oncology, 2003. 22, 47.	Abstract
Gordon, D.H., Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clinical Breast Cancer, 2005. 6(2): p. 125-31.	Narrative review
Gralow, J., et al. Effects of denosumab treatment in breast cancer patients with bone metastases and elevated bone resorption levels after therapy with intravenous bisphosphonates: results of a phase 2 randomized trial. 2008.	Abstract
Groenen, K.H., et al., The effect of radiotherapy, and radiotherapy combined with bisphosphonates or RANK ligand inhibitors on bone quality in bone metastases. A systematic review. Radiotherapy & Oncology, 2016. 119(2): p. 194-201.	Hypercalciëmie niet gerapporteerd, geen RCTs
Gul, G., et al., A comprehensive review of denosumab for bone metastasis in patients with solid tumors. Current Medical Research & Opinion, 2016. 32(1): p. 133-45.	Narrative review
Hadji, P., Managing bone health with zoledronic acid: a review of randomized clinical study results. Climacteric, 2011. 14(3): p. 321-32.	Narrative review
Hageman, K., et al., The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Annals of Pharmacotherapy, 2013. 47(7-8): p. 1069-74.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Hahn, N.M., et al., Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. Clinical Genitourinary Cancer, 2014. 12(1): p. 33-40.e4.	Geen RCT
Han, J., et al. Comparison of clinical effect in treatment of bone tumor between zoledronic acid needle and ibandronate needle. Pakistan journal of pharmaceutical sciences, 2018. 31, 1683-1686.	Hypercalciëmie niet gerapporteerd
Hasegawa, Y., et al., Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE Study). PLoS ONE, 2015. 10(12).	Geen botmetastasen
He, W., W. Wei, and H. Zhang Clinical research on the zoledronic acid monotherapy in the treatment of lung cancer combined with bone metastasis. Anti-tumor pharmacy, 2013. 3, 375-377 DOI: 10.3969/j.issn.2095-1264.2013.093.	Chinees
Heim, M. Prospective randomized trial of clodronate in multiple myeloma. Annals of oncology, 1994. 5, 200.	Geen full-text
Heim, M.E., et al., Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie, 1995. 18(5): p. 439-448.	Sommige patiënten hadden hypercalciëmie bij inclusie
Hendriks, L.E., et al., Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2016. 11(2): p. 155-73.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Henry, D., et al., Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Supportive Care in Cancer, 2014. 22(3): p. 679-87.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Henry, D.H., et al., Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology, 2011. 29(9): p. 1125-32.	Hypercalciëmie niet gerapporteerd, SREs en toxicity

Heras, P., A. Hatzopoulos, and D. Mitsibounas Efficacy of ibandronate for the prevention of skeletal-related events in breast cancer patients with metastatic bone disease. <i>European journal of cancer</i> , 2005. 3, 121.	Abstract
Heras, P., et al. Ibandronate is effective in preventing skeletal events in patients with bone metastases secondary to colorectal carcinoma. Annual meeting proceedings of the american society of clinical oncology, 2005. 23, 280.	Abstract
Heras, P., et al., A comparative study of intravenous ibandronate and pamidronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain. <i>American Journal of Therapeutics</i> , 2011. 18(5): p. 340-2.	Geen RCT
Heras, P., et al., Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. <i>European Journal of Cancer Care</i> , 2009. 18(6): p. 653-6.	Hypercalciëmie niet gerapporteerd, SREs en toxicity
Heras, P., et al., Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. <i>European Journal of Cancer Care</i> , 2007. 16(6): p. 539-42.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Hilton, J., et al. Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer. <i>Journal of bone oncology</i> , 2018. 10, DOI: 10.1016/j.jbo.2017.11.001.	Hypercalciëmie niet gerapporteerd, wel SREs
Himmelstein, A.L., et al., Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. <i>JAMA</i> , 2017. 317(1): p. 48-58.	Hypercalciëmie niet gerapporteerd, wel SREs
Hortobagyi, G., et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial. <i>Journal of clinical oncology</i> , 2014. 32.	Abstract
Hortobagyi, G.N., et al., Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017. 3(7): p. 906-912.	Hypercalciëmie niet gerapporteerd, wel SREs en toxicity
Hoskin, P., et al. A multicentre randomised trial of ibandronate compared to single dose radiotherapy for localised metastatic bone pain in prostate cancer (RIB). <i>European journal of cancer</i> , 2011. 47, 6 DOI: 10.1016/S0959-8049%2811%2970106-X.	Abstract
Hoskin, P., et al., A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015. 107(10).	Hypercalciëmie niet gerapporteerd
Hu, Z., et al., The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. <i>Supportive Care in Cancer</i> , 2020. 28(7): p. 3291-3301.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Huang, S.Y., et al., Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis. <i>Advances in Therapy</i> , 2020. 37(7): p. 3404-3416.	Subgroep analyse
Hultborn, R., et al., Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study. <i>Acta Oncologica</i> , 1996. 35 Suppl 5: p. 73-4.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Hultborn, R., et al., Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. <i>Anticancer Research</i> , 1999. 19(4C): p. 3383-92.	Geen full-text
Hutton, B., et al., A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer. <i>Journal of Bone Oncology</i> , 2013. 2(3): p. 123-131.	Hypercalciëmie niet gerapporteerd, wel



	SREs en safety; gaat over doseringen
Isla, D., et al., Zoledronic acid in lung cancer with bone metastases: a review. <i>Expert Review of Anticancer Therapy</i> , 2013. 13(4): p. 421-6.	Narrative review
Jagdev, S., et al. Clodronate compared to ibandronate breast cancer bone metastases patient preference study. <i>Proceedings of the american society of clinical oncology</i> , 2007. 25.	Abstract
Jagdev, S.P., et al., Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. <i>Annals of Oncology</i> , 2001. 12(10): p. 1433-8.	Hypercalciëmie niet gerapporteerd
Jang, A., et al., Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2020. 4(2): p. 93-102.	Geen kwaliteitsbeoordeling van geïnccludeerde studies, enkel PubMed
Jiang, L., et al., Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials. <i>Journal of Orthopaedic Surgery</i> , 2021. 16(1): p. 400.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Jiang, Z., et al. Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors. <i>Journal of clinical oncology</i> , 2016. 34.	Abstract
Jung, A., et al., Use of dichloromethylene diphosphonate in metastatic bone disease. <i>New England Journal of Medicine</i> , 1983. 308(25): p. 1499-501.	Serum Ca, geen %
Kamba, T., et al., A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. <i>International Journal of Clinical Oncology</i> , 2017. 22(1): p. 166-173.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Klotz, L., et al. Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: results from a phase III trial of denosumab for the prevention of skeletal-related events. <i>Journal of clinical oncology</i> , 2014. 32.	Abstract
Knauf, U., et al. Compare - results of a randomised study to assess the renal safety and efficacy of ibandronate and zoledronate in multiple myeloma patients. <i>Haematologica</i> , 2010. 92, 398.	Abstract
Knight, R. Phase III randomised study of zoledronate versus pamidronate in patients with cancer related bone lesions due to multiple myeloma or breast cancer. National institutes of health, clinicaltrials.gov [ <a href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</a> ], 2003.	Trial protocol
Knight, R. Phase III randomised study of zoledronate versus pamidronate in patients with cancer related bone lesions due to multiple myeloma or breast cancer. Physician data query (PDQ), 1999.	Geen full-text
Koeberle, D., et al., Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial. <i>Supportive Care in Cancer</i> , 1999. 7(1): p. 21-27.	Hypercalciëmie niet gerapporteerd (wel QOL)
Kohno, N., et al. A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. <i>Annual meeting proceedings of the american society of clinical oncology</i> , 2004. 43.	Abstract
Kohno, N.A.K.M.H.N.S.A.T.I.Y.W.T.G.C.O.Y.T.S. Zoledronic acid reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer. 2004.	Abstract

Kraj, M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate in the treatment of myeloma bone disease. <i>Acta haematologica Polonica</i> , 2004. 35, 227-241.	Geen full-text
Kraj, M., et al. The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma. <i>Acta haematologica Polonica</i> , 2000. 31, 379-389.	Geen full-text
Kraj, M., et al. The effects of 8-year pamidronate treatment on skeletal morbidity in patients with advanced multiple myeloma. <i>Nowotwory</i> , 2004. 54, 570-577.	Sommige patiënten hadden hyperCa bij inclusie
Kraj, M., et al., Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). <i>Acta Poloniae Pharmaceutica</i> , 2002. 59(6): p. 478-82.	Sommige patiënten hadden hyperCa bij inclusie
Kraj, M., et al., Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. <i>Acta Poloniae Pharmaceutica</i> , 2000. 57 Suppl: p. 113-6.	Sommige patiënten hadden hypercalciëmie bij inclusie
Kumar, A., et al., Management of multiple myeloma: a systematic review and critical appraisal of published studies. <i>Lancet Oncology</i> , 2003. 4(5): p. 293-304.	Narrative review
Kyle, R.A., et al., American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2007. 25(17): p. 2464-72.	Geen kwaliteitsbeoordeling van geïncludeerde studies
Kylmala, T., et al., Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer. <i>British Journal of Cancer</i> , 1997. 76(7): p. 939-42.	Serum Ca, geen %
Kylmala, T., et al., Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. <i>European Journal of Cancer</i> , 1993. 29A(6): p. 821-5.	Serum Ca, geen %
Lee, B.L., M.J. Higgins, and P.E. Goss, Denosumab and the current status of bone-modifying drugs in breast cancer. <i>Acta Oncologica</i> , 2012. 51(2): p. 157-67.	Narrative review
Leng, Y., S. Chen, and H. Shi Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma. <i>Hang tian yi xue yu yi xue gong cheng [Space medicine &amp; medical engineering]</i> , 2002. 15, 377-378.	Chinees
Leung, A.K.C., Clinical effectiveness and safety of denosumab for treating bone metastasis: A systemic review of randomized trials. <i>Journal of Pain Management</i> , 2018. 11(1): p. 7-28.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
LeVasseur, N., et al., Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2016. 50: p. 183-193.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Li, F., et al., An effective therapy to painful bone metastases: cryoablation combined with zoledronic acid. <i>Pathology Oncology Research</i> , 2014. 20(4): p. 885-91.	Sommige patiënten hadden hyperCa bij inclusie
Li, F., et al., Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases. <i>Experimental and Therapeutic Medicine</i> , 2014. 8(2): p. 539-544.	Sommige patiënten hadden hyperCa bij inclusie
Li, H., et al. A multicenter, randomized, double-blind, phase III trial comparing denosumab biosimilar QL1206 and denosumab in patients with bone metastases from solid tumors. <i>Journal of clinical oncology</i> , 2022. 40, DOI: 10.1200/JCO.2022.40.16_suppl.2526.	Abstract

Lichinister, M., et al. Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparison of bone turnover markers. <i>European journal of cancer</i> , 2005. 3, 113.	Abstract
Lipton, A., et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. <i>Journal of clinical oncology</i> , 2014. 32.	Abstract
Lipton, A., et al. Prevention of skeletal-related events with denosumab or zoledronic acid - Combined analysis from 3 registrational trials. <i>European journal of cancer</i> , 2011. 47, S240 DOI: 10.1016/S0959-8049%2811%2971134-0.	Abstract
Lipton, A., et al. Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). <i>Journal of clinical oncology: ASCO annual meeting proceedings</i> , 2006. 24, 512.	Abstract
Lipton, A., et al., Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. <i>European Journal of Cancer</i> , 2016. 53: p. 75-83.	Hypercalciëmie niet gerapporteerd, geen systematische search om deze RCTs te identificeren
Lipton, A., et al., Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. <i>Clinical Cancer Research</i> , 2008. 14(20): p. 6690-6696.	Hypercalciëmie niet gerapporteerd, wel safety
Lipton, A., et al., Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. <i>Annals of Oncology</i> , 1994. 5 Suppl 7: p. S31-5.	Geen full-text
Lipton, A., et al., Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. <i>Journal of Clinical Oncology</i> , 2007. 25(28): p. 4431-4437.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Lipton, A., et al., Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. <i>European Journal of Cancer</i> , 2012. 48(16): p. 3082-92.	Pooled analysis van 3 RCTs, maar geen systematische search om deze RCTs te identificeren
Lipton, A., et al., The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. <i>Cancer Investigation</i> , 2002. 20 Suppl 2: p. 45-54.	Narrative review
Liu, J., et al., Bisphosphonates in the Treatment of Patients With Metastatic Breast, Lung, and Prostate Cancer: A Meta-Analysis. <i>Medicine</i> , 2015. 94(46): p. e2014.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Lopez-Olivo, M.A., et al., Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2012. 20(11): p. 2985-98.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Luedders, D.W., et al., Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases. <i>Anticancer Research</i> , 2015. 35(3): p. 1797-802.	Geen SREs gerapporteerd
Lyubimova, N.V., et al., Renal Safety of Intravenous Ibandronic Acid in Breast Cancer Patients with Metastatic Bone Disease. <i>Clinical Drug Investigation</i> , 2003. 23(11): p. 707-716.	Geen SREs gerapporteerd

Ma, C.-R., et al. Effects of PTD versus TD regimens for multiple myeloma: a randomized controlled trial. Chinese journal of evidence-based medicine, 2009. 9, 824-827.	Geen full-text
Macherey, S., et al., Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews, 2017. 12: p. CD006250.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Mackiewicz-Wysocka, M., M. Pankowska, and P.J. Wysocki, Progress in the treatment of bone metastases in cancer patients. Expert Opinion on Investigational Drugs, 2012. 21(6): p. 785-95.	Narrative review
Macpherson, I.R., et al., Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 2015. 15(2): p. 117-27.	Hypercalciëmie niet gerapporteerd, wel safety
Mannix, K., et al., Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care. Palliative Medicine, 2000. 14(6): p. 455-61.	Geen kwaliteitsbeoordeling van geïncludeerde studies
Martin, M., et al. Benefit of denosumab therapy in patients with bone metastases from breast cancer: a number-needed-to-treat (NNT) analysis. Breast (Edinburgh, Scotland), 2011. 20, S85.	Abstract
Martoni, A., et al., Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology, 1991. 48(2): p. 97-101.	Geen full-text
Marx, G., et al. Denosumab or zoledronic acid therapy on pain interference and cancer-specific quality of life in patients with castrate-resistant prostate cancer and bone metastases. BJU international, 2014. 113, 24.	Abstract
Mason, M.D., et al., Oral sodium clodronate for nonmetastatic prostate cancer - Results of a randomized double-blind placebo-controlled trial: Medical research council PR04 (ISRCTN61384873). Journal of the National Cancer Institute, 2007. 99(10): p. 765-776.	Geen botmetastasen
Matuoka, J.Y., J.G. Kahn, and S.R. Secoli, Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. European Journal of Health Economics, 2019. 20(4): p. 487-499.	SR van economische studies
McCloskey, E.V., et al., A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Journal of Haematology, 1998. 100(2): p. 317-325.	Sommige patiënten hadden hyperCa bij inclusie
McCloskey, E.V., et al., Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. British Journal of Haematology, 2001. 113(4): p. 1035-1043.	Sommige patiënten hadden hyperCa bij inclusie
McLachlan, S.A., et al., Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. Clinical Drug Investigation, 2006. 26(1): p. 43-8.	Hypercalciëmie niet gerapporteerd
Mei, M., et al., Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials. Current Problems in Cancer, 2020. 44(2): p. 100507.	Geen botmetastasen
Menshaw, A., et al., Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Supportive Care in Cancer, 2018. 26(4): p. 1029-1038.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Meulenbeld, H.J., et al., Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). European Journal of Cancer, 2012. 48(16): p. 2993-3000.	Geen SREs gerapporteerd

Mhaskar, R., et al., Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database of Systematic Reviews, 2012(5): p. CD003188.	Updated
Mhaskar, R., et al., Bisphosphonates in multiple myeloma. Cochrane Database of Systematic Reviews, 2010(3): p. CD003188.	Updated
Michaelson, M.D., et al., Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer, 2006. 107(3): p. 530-5.	Geen SREs gerapporteerd
Micke, O., et al. Combination of ibandronate and radiotherapy in metastatic bone disease - final results of a randomized phase II trial. European journal of cancer, 2003. 1, S150.	Abstract
Micke, O., et al. Combination of ibandronate and radiotherapy in metastatic bone disease - results of a randomized study. Proceedings of the american society of clinical oncology, 2003. 759.	Abstract
Millward, M., et al. A randomized trial of the addition of Disodium Pamidronate to endocrine therapy for advanced breast cancer with bone metastases. Proceedings of the american society of clinical oncology, 1991. 10, 42, Abstract 43.	Abstract
Miyashita, H., et al., Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis. Supportive Care in Cancer, 2022. 30(1): p. 855-863.	Geen botmetastasen
Moiseyenko, V., et al. Randomized Trial of Two Intravenous Schedules of Clodronate (Cl) in Patients with Painful Bone Metastases. Proc-eur-soc-med-oncol, 1996. Abstract #698.	Abstract
Moiseyenko, Y., et al. Randomized trial of two intravenous schedules of bonephos (clodronate) in patients with painful bone metastases. Voprosy onkologii (matters of oncology), 1998. 44, 725-728.	Russisch
Morgan, G., et al. Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results. Journal of clinical oncology, 2012. 30.	Abstract
Morgan, G., et al. Zoledronic acid (ZOL) prolongs time to first skeletal-related event (SRE) and survival versus clodronate in newly diagnosed multiple myeloma (MM): MRC myeloma IX trial results. Haematologica, 2010. 92, 232.	Abstract
Morgan, G.J., et al., Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood, 2012. 119(23): p. 5374-83.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Morgan, G.J., et al., Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncology, 2011. 12(8): p. 743-52.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Morgan, G.J., et al., First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet, 2010. 376(9757): p. 1989-99.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Morgan, G.J., et al., Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clinical Cancer Research, 2013. 19(21): p. 6030-8.	Geen SREs gerapporteerd
Muller, A., et al. Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE). Cancer research, 2019. 79, DOI: 10.1158/1538-7445.SABCS18-P1-18-01.	Abstract

Musto, P., et al. Final Analysis of a Multicenter, Randomised Study Comparing Zoledronate vs Observation in Patients with Asymptomatic Myeloma. <i>Blood</i> , 2007. 110.	Abstract
Musto, P., et al. Zoledronate for early-stage, untreated myeloma: an interim report of a randomized study. <i>Journal of clinical oncology : ASCO annual meeting proceedings</i> , 2004. 22, 600.	Abstract
Musto, P., et al., A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. <i>Cancer</i> , 2008. 113(7): p. 1588-95.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Mystakidou, K., et al., A prospective randomized controlled clinical trial of zoledronic acid for bone metastases. <i>American Journal of Hospice &amp; Palliative Medicine</i> , 2006. 23(1): p. 41-50.	Slechts 1 zin over calciëmie, vergelijking van verschillende toedieningsfrequenties
Mystakidou, K., et al., Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. <i>Journal of Cancer Research &amp; Clinical Oncology</i> , 2008. 134(12): p. 1303-10.	Slechts 1 zin over calciëmie, vergelijking van verschillende toedieningswijzes
Ng, T.L., et al., Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. <i>Supportive Care in Cancer</i> , 2021. 29(2): p. 925-943.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Nozawa, M., et al., Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis. <i>International Journal of Clinical Oncology</i> , 2014. 19(4): p. 693-701.	Geen RCT
O'Carrigan, B., et al., Bisphosphonates and other bone agents for breast cancer. <i>Cochrane Database of Systematic Reviews</i> , 2017. 2017(10).	Hypercalciëmie niet apart gerapporteerd, wel SREs, QOL en safety
O'Rourke, N., E. McCloskey, and J. Kanis Single intravenous infusion of Clodronate in control of metastatic bone pain - a double blind trial. <i>Eur-j-cancer</i> , 1993. 29f, S202.	Abstract
O'Rourke, N., et al., Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. <i>Journal of Clinical Oncology</i> , 1995. 13(4): p. 929-34.	Hypercalciëmie niet gerapporteerd, wel safety
Okada, H., et al. Randomized phase ii trial of zoledronic acid in combination with docetaxel in previously treated non-small-cell lung cancer (NSCLC) patients with bone metastases: WJTOG3806. <i>Annals of oncology</i> , 2012. 23, xi43 DOI: 10.1093/annonc/mds559.	Abstract
Okegawa, T., et al., Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. <i>Anticancer Research</i> , 2014. 34(8): p. 4415-20.	Geen RCT
Palmieri, C., J.R. Fullarton, and J. Brown, Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. <i>Clinical Cancer Research</i> , 2013. 19(24): p. 6863-72.	Geen kwaliteitsbeoordeling van geïnccludeerde studies, enkel PubMed
Pandya, K.J., et al., Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2010. 67(3): p. 330-338.	Geen botmetastasen
Papamerkouriou, Y.M., et al., Treatment of multiple myeloma bone disease: experimental and clinical data. <i>Expert Opinion on Biological Therapy</i> , 2015. 15(2): p. 213-30.	Narrative review

Parvez, T., A. Sheikh, and A. Ahmed Effect of pamidronate on pain control in breast cancer patients. <i>Journal of the College of Physicians and Surgeons--Pakistan : JCPSP</i> , 2002. 12, 32-35.	Geen full-text
Patel, S.H., et al., Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies. <i>European Urology Focus</i> , 2020. 6(1): p. 17-25.	Geen kwaliteitsbeoordeling van geïncludeerde studies
Paterson, A., et al. Clodronate decreases skeletal morbidity in patients with bone metastases from breast cancer: a double-blind controlled trial. <i>Proceedings of the american society of clinical oncology</i> , 1992. 11, 49, Abstract 21.	Abstract
Paterson, A.H., et al., Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. <i>Journal of Clinical Oncology</i> , 1993. 11(1): p. 59-65.	Sommige patiënten hadden hyperCa bij inclusie
Patrick, D., et al. Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM). <i>Journal of clinical oncology</i> , 2014. 32.	Abstract
Pecherstorfer, M., et al., Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. <i>Clinical Drug Investigation</i> , 2006. 26(6): p. 315-22.	Geen SREs gerapporteerd
Peddi, P., et al., Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2013. 39(1): p. 97-104.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Peters, S., et al. A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: the ETOP and EORTC SPLENDOUR trial. <i>Annals of oncology</i> , 2018. 29, viii498- DOI: 10.1093/annonc/mdy292.008.	Abstract
Piga, A., et al., A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. <i>Journal of Experimental &amp; Clinical Cancer Research</i> , 1998. 17(2): p. 213-7.	Geen full-text
Pittari, G., et al. Intravenous neridronate for treatment of skeletal involvement in patients undergoing autologous stem cell transplantation for multiple myeloma. <i>Bone marrow transplantation</i> , 2004. 33, S162.	Abstract
Pittman, K., et al. Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: a comparison with skeletal-related events. <i>BJU international</i> , 2014. 113, 23-.	Geen full-text
Pivot, X., et al., Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial. <i>Breast</i> , 2011. 20(6): p. 510-4.	Vergelijking van verschillende doseringen
Porta-Sales, J., et al., Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project. <i>Palliative Medicine</i> , 2017. 31(1): p. 5-25.	Focus op pijn als uitkomst
Raje, N., et al. A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma. <i>Journal of clinical oncology</i> , 2014. 32.	Abstract
Raje, N., et al. Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: an international, randomized, double-blind trial. <i>Journal of clinical oncology</i> , 2015. 33.	Abstract

Raje, N., et al. Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. <i>Journal of clinical oncology</i> , 2017. 35.	Abstract
Raje, N., et al., Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2018. 19(3): p. 370-381.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Richardson, G., et al. Comparison of denosumab versus zoledronic acid (ZA) for the prevention of skeletal-related events in patients with bone metastases from solid tumors. <i>Asia-Pacific journal of clinical oncology</i> , 2011. 7, 91 DOI: 10.1111/j.1743-7563.2011.01477.x.	Abstract
Richardson, G., et al. Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: a number needed to treat (NNT) analysis. <i>Journal of clinical oncology</i> , 2011. 29.	Abstract
Ripamonti, C., et al., Role of pamidronate disodium in the treatment of metastatic bone disease. <i>Tumori</i> , 1998. 84(4): p. 442-55.	Narrative review
Ritchie, D., C. Bray, and P. Canney A randomized phase 2 study of a loading dose of ibandronate in patients with bone metastases from breast cancer. <i>Cancer research</i> , 2011. 71, DOI: 10.1158/0008-5472.SABCS11-P4-16-05.	Abstract
Rosen, L., et al. Long-term (25-month) efficacy and safety of 4 mg zoledronic acid for the treatment of multiple myeloma bone disease: a randomized, phase III, comparative trial with pamidronate. <i>Blood</i> , 2002. 100.	Abstract
Rosen, L.S., et al., Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. <i>Cancer</i> , 2004. 100(1): p. 36-43.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Rosen, L.S., et al., Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. <i>Cancer Journal</i> , 2001. 7(5): p. 377-87.	Geen full-text
Ryan, C.W., et al., Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. <i>BJU International</i> , 2007. 100(1): p. 70-5.	Niet alle patiënten hadden botmetastasen
Saad, F. and J. Eastham, Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. <i>Urology</i> , 2010. 76(5): p. 1175-81.	Hypercalciëmie niet gerapporteerd, wel SREs
Saad, F., et al., A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. <i>Journal of the National Cancer Institute</i> , 2002. 94(19): p. 1458-68.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Saad, F., et al., Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. <i>Clinical Genitourinary Cancer</i> , 2007. 5(6): p. 390-6.	Secondary analysis
Saad, F., et al., Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. <i>Journal of the National Cancer Institute</i> , 2004. 96(11): p. 879-82.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Salamanna, F., et al., Clinical characteristics, treatment modalities, and potential contributing and prognostic factors in patients with bone metastases from gynecological cancers: A systematic review. <i>Diagnostics</i> , 2021. 11(9).	Foute scope, geen RCTs
Scagliotti, G., et al. Effect of denosumab versus zoledronic acid on overall survival in patients with lung cancer and bone metastases: results from a randomized phase 3 study. <i>Journal of thoracic oncology</i> , 2012. 7, S61-s62 DOI: 10.1097/JTO.0b013e318253d2ff.	Abstract



Scagliotti, G.V., et al., Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. <i>Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer</i> , 2012. 7(12): p. 1823-1829.	Geen SREs gerapporteerd
Scagliotti, G.V., et al., Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study. <i>Annals of Oncology</i> , 2012. 23(8): p. 2082-2087.	Geen botmetastasen
Seider, M.J., et al., Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. <i>Annals of Nuclear Medicine</i> , 2018. 32(8): p. 553-560.	Hypercalciëmie niet gerapporteerd, vergelijking niet relevant voor PICO
Semiglazov, V. and V. Moiseyenko Study of two intravenous schedules of clodronate (CL) in patients with bone metastases. <i>Proc-eur-cancer-conf (ECCO)</i> , 1997. Abstract #240.	Abstract
Serpa Neto, A., et al., Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2012. 15(1): p. 36-44.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Shapiro, C. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. <i>Breast diseases</i> , 2013. 24, 220-221 DOI: 10.1016/j.breastdis.2013.07.037.	Geen full-text
Shi, X., et al. Clinical comparative study of zoledronic acid versus pamidronate disodium in the treatment of pain of skeletal metastases lung cancer. <i>Chinese journal of cancer prevention and treatment</i> , 2008. 15, 707-708.	Geen full-text
Shore, N., et al. Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: subgroup analyses by prior SRE and baseline pain. <i>Journal of clinical oncology</i> , 2011. 29.	Abstract
Shucaï, Z., L. Guimei, and H. Fanbin A clinical trial of Bonin in bone metastases of lung cancer. <i>Chinese journal of clinical oncology</i> , 1999. 26, 445-447.	Geen full-text
Siris, E.S., et al., Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. <i>New England Journal of Medicine</i> , 1980. 302(6): p. 310-5.	Sommige patiënten hadden hyperCa bij inclusie
Siris, E.S., G.A. Hyman, and R.E. Canfield, Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. <i>American Journal of Medicine</i> , 1983. 74(3): p. 401-6.	Sommige patiënten hadden hyperCa bij inclusie
Smith, A.G., et al., Home care versus hospital care in patients with multiple myeloma treated with pamidronate. <i>International Journal of Palliative Nursing</i> , 2004. 10(3): p. 144-9.	Geen full-text
Smith, J.A., Jr., Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. <i>Journal of Urology</i> , 1989. 141(1): p. 85-7.	Geen full-text
Smith, M., et al. Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: a comparison with skeletal-related events. <i>Journal of clinical oncology</i> , 2014. 32.	Abstract
Smith, M.R., et al., Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. <i>Annals of Oncology</i> , 2015. 26(2): p. 368-74.	Hypercalciëmie niet gerapporteerd, wel SREs
Smith, M.R., et al., Denosumab in men receiving androgen-deprivation therapy for prostate cancer. <i>New England Journal of Medicine</i> , 2009. 361(8): p. 745-755.	Geen botmetastasen

Smith, M.R., et al., Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). <i>Journal of Clinical Oncology</i> , 2014. 32(11): p. 1143-50.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Solomayer, E.F., et al., Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. <i>Annals of Oncology</i> , 2012. 23(9): p. 2271-2277.	Geen botmetastasen
Spencer, A., et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. <i>Journal of oncology pharmacy practice</i> , 2012. 18, 22-23 DOI: 10.1177/1078155212439813.	Geen full-text
Spencer, A., et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post-hoc analysis of the effect of denosumab treatment. <i>Asia-Pacific journal of clinical oncology</i> , 2012. 8, 45-46 DOI: 10.1111/j.1743-7563.2012.01580.x.	Geen full-text
Spencer, A., et al., Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. <i>BMC Clinical Pharmacology</i> , 2008. 8: p. 2.	Geen RCT
Stopeck, A., et al. A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases. 2010. 69, DOI: 10.1158/0008-5472.SABCS-09-22.	Abstract
Stopeck, A., et al. Abstract P6-14-01: effect of Denosumab Versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: results from the Extended Blinded Treatment Phase. 2010. 70, DOI: 10.1158/0008-5472.SABCS10-P6-14-01.	Abstract
Stopeck, A., et al. Abstract P6-14-09: acute-Phase Reactions Following Treatment with Zoledronic Acid or Denosumab: results from a Randomized, Controlled Phase 3 Study in Patients with Breast Cancer and Bone Metastases. 2010. 70, DOI: 10.1158/0008-5472.SABCS10-P6-14-09.	Abstract
Stopeck, A., et al. AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. <i>European journal of cancer</i> , 2012. 48, S3 DOI: 10.1016/j.ejca.2012.02.016.	Abstract
Stopeck, A., et al. Denosumab versus zoledronic acid for the prevention of skeletal-related events in patients with bone metastases secondary to solid tumours: an integrated analysis of three phase 3 studies. <i>European journal of cancer</i> , 2012. 48, S8 DOI: 10.1016/j.ejca.2012.02.030.	Abstract
Stopeck, A.T., et al., Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. <i>Supportive Care in Cancer</i> , 2016. 24(1): p. 447-455.	Extensie van RCT
Strang, P., et al., The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. <i>Anticancer Research</i> , 1997. 17(6D): p. 4717-21.	Geen full-text
Suarez, T., et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. <i>Journal of clinical oncology</i> , 2006. 24, 483s.	Abstract
Sun, H., J. Zhou, and Y. Zhang Clinical research on zoledronic acid for injection in treatment of the pain of osteolytic osseous metastasis caused by malignancy. <i>Chinese journal of clinical oncology</i> , 2005. 32, 885-888.	Geen full-text

Sun, L. and S. Yu, Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. American Journal of Clinical Oncology, 2013. 36(4): p. 399-403.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Taneja, S.S., Re: Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical Trial. Journal of Urology, 2017. 198(3): p. 484.	Abstract
Taube, T., et al., Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study. European Journal of Cancer, 1993. 29A(12): p. 1677-81.	Serum Ca, geen %
Taube, T., et al., The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. European Journal of Cancer Part A: General Topics, 1994. 30(6): p. 751-758.	Serum Ca, geen %
Terpos, E., et al. Comparison of denosumab with zoledronic acid for the treatment of bone disease in patients with newly diagnosed multiple myeloma; An international, randomized, double blind trial. Haematologica, 2017. 102, 318-.	Abstract
Terpos, E., et al., The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology, 2009. 20(8): p. 1303-17.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Terpos, E., et al., Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, 2021. 22(3): p. e119-e130.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Tesfamariam, Y., et al., Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis. Critical Reviews in Oncology-Hematology, 2019. 137: p. 1-8.	Geen toegang tot de supplementaire figuren
Tesfamariam, Y.M., et al., Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: A Cochrane Review and network meta-analysis. Cochrane Database of Systematic Reviews, 2018. 2018(5).	Updated
Tolia, M., et al., The key role of bisphosphonates in the supportive care of cancer patients. Anticancer Research, 2014. 34(1): p. 23-37.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Tripathy, D. and B. Bergstrom Effect of intravenous and oral ibandronate on the need for analgesic interventions for metastatic bone pain: phase III trial results. European journal of cancer, 2005. 3, 113.	Abstract
Tripathy, D., et al. Oral ibandronate lowers the incidence of skeletal complications in breast cancer patients with bone metastases. American society of clinical oncology, 2002. 21, 45a.	Abstract
Tripathy, D., et al., Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Annals of Oncology, 2004. 15(5): p. 743-50.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Tubiana-Hulin, M., et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du cancer, 2001. 88, 701-707.	Geen full-text
Tubiana, H.M., et al. Double blind placebo controlled trial of oral clodronate in patients with bone metastases from breast cancer. Effect on induced hyperosteolysis. Proceedings of the american society of clinical oncology, 1995. 14, 523, Abstract 1718.	Abstract

Ucci, G., et al. Clodronate parenteral administration as prophylaxis in multiple myeloma. A prospective, controlled, randomized trial. <i>Tumori</i> , 1993. 79 Suppl, 74.	Geen full-text
Ueno, S., et al., Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. <i>Anticancer Research</i> , 2013. 33(9): p. 3837-44.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Utkan, G., A. Buyukcelik, and B. Yalcyn, The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer. <i>Annals of Oncology</i> , 2004. 15(10): p. 1574; author reply 1574-5.	Letter
Vadhan-Raj, S., et al., Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. <i>Annals of Oncology</i> , 2012. 23(12): p. 3045-3051.	Hypercalciëmie niet gerapporteerd, wel QOL
Valachis, A., et al., Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. <i>Oncologist</i> , 2013. 18(4): p. 353-61.	Geen botmetastasen
Vale, C.L., et al., Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology</i> , 2016. 17(2): p. 243-256.	Geen SREs gerapporteerd
van Holten-Verzantvoort, A.T., et al., The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. <i>European Journal of Cancer</i> , 1991. 27(5): p. 544-9.	Enkel QOL
Van Poznak, C., et al., Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2017. 35(35): p. 3978-3986.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Van Poznak, C.H., et al., American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2011. 29(9): p. 1221-7.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Vidula, N., et al. Long term follow up (LTFU) of adjuvant zoledronic acid (ZOL) in high risk early stage breast cancer (ESBC) defined by bone marrow (BM) disseminated tumor cells (DTC). <i>Journal of clinical oncology. Conference: 2017 annual meeting of the american society of clinical oncology, ASCO. United states, 2017.</i> 35.	Abstract
Vliek, S., et al. The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-04). <i>Cancer research. Conference: 39th annual CTRC-AACR san antonio breast cancer symposium. United states, 2017.</i> 77, DOI: 10.1158/1538-7445.SABCS16-S6-02.	Abstract
von Au, A., et al., Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: A randomized, open-label, non-inferiority phase III trial. <i>OncoTargets and Therapy</i> , 2016. 9: p. 4173-4180.	Hypercalciëmie niet gerapporteerd, wel safety
von Minckwitz, G., et al., Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). <i>European Journal of Cancer</i> , 2016. 64: p. 12-21.	Geen botmetastasen
von Moos, R., et al., Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. <i>Supportive Care in Cancer</i> , 2013. 21(12): p. 3497-507.	Hypercalciëmie niet gerapporteerd, wel QOL

von Moos, R., et al., Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. <i>Annals of Oncology</i> , 2008. 19(7): p. 1266-1270.	Hypercalciëmie niet gerapporteerd, wel safety
Wang, D., et al. Pamidronate in treatment of pain caused by bone metastasis. <i>Ai zheng [Chinese journal of cancer]</i> , 2004. 23, 1467-1469.	Chinees
Wang, F., et al., Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases. <i>Medical Oncology</i> , 2013. 30(3): p. 657.	Abstract
Wang, R.F., et al., A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. <i>Medical Principles &amp; Practice</i> , 2003. 12(2): p. 97-101.	Vergelijking niet relevant voor PICO
Wang, T., et al., Clinical effect of intravenous infusion of zoledronic acid combined with oral medication of cinobufagin in the treatment of metastatic bone tumors. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2018. 31(4(Special)): p. 1609-1612.	Geen full-text
Wang, X., et al., Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials. <i>Oncology Letters</i> , 2014. 7(6): p. 1997-2002.	Hypercalciëmie niet gerapporteerd, wel SREs, QOL en safety
Wang, X., X. Yan, and Y. Li, A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma. <i>International Journal of Clinical and Experimental Medicine</i> , 2015. 8(5): p. 6743-6754.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Wang, Y., et al., Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013. 14(3): p. 254-60.	Hypercalciëmie niet gerapporteerd
Wang, Y., et al., Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis. <i>Annals of Palliative Medicine</i> , 2021. 10(11): p. 11950-11959.	Hypercalciëmie niet gerapporteerd, wel safety
Wang, Z., et al., Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. <i>Oncologist</i> , 2015. 20(4): p. 440-9.	Hypercalciëmie niet gerapporteerd, wel SREs
Wardley, A., et al., Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. <i>British Journal of Cancer</i> , 2005. 92(10): p. 1869-76.	Hypercalciëmie niet gerapporteerd, wel QOL; vergelijking van verschillende toedieningswijzen
Wardley, A., J.-J. Body, and M. Neary A time-in-motion study of oral ibandronate versus iv zoledronic acid for treatment of metastatic bone disease in breast cancer patients. <i>Annual meeting proceedings of the american society of clinical oncology</i> , 2005. 23, 558.	Abstract
Weinfurt, K.P., et al., Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. <i>Annals of Oncology</i> , 2006. 17(6): p. 986-9.	Geen SREs gerapporteerd
Westermann, A.M., Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. <i>Annals of Oncology</i> , 2005. 16(3): p. 513; author reply 513.	Letter
Witzig, T., et al. A phase III randomized trial of thalidomide (THAL) plus zoledronic acid (ZLD) versus zoledronic acid alone in patients with early stage multiple myeloma (MC0289). <i>Blood</i> , 2010. 116.	Abstract
Witzig, T.E., et al., A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. <i>Leukemia</i> , 2013. 27(1): p. 220-5.	Geen SREs gerapporteerd
Wong, M.H., M.R. Stockler, and N. Pavlakis, Bisphosphonates and other bone agents for breast cancer. <i>Cochrane Database of Systematic Reviews</i> , 2012(2): p. CD003474.	Updated

Wong, R. and P.J. Wiffen, Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews, 2002(2): p. CD002068.	Updated
Wong, R., et al. A randomized double blind placebo controlled trial of radiotherapy (XRT) with or without single dose pamidronate (PAM) pain relief in patients with painful bone metastases. Proceedings of the american society of clinical oncology, 2003. 771.	Abstract
Wong, R.K.S. and P.J. Wiffen, Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews, 2009(4).	Geen SREs gerapporteerd
Wu, C., H. Jiang, and J. Chen, A Systematic Review and Meta-Analysis about the Effect of Bisphosphonates on the Risk of Skeletal-Related Event in Men with Prostate Cancer. Current Medicinal Chemistry - Anti-Cancer Agents, 2020. 20(13): p. 1604-1612.	Geen full-text
Xu, C.Y., et al., Curative effects of zoledronic acid combined with calcitonin on the treatment of bone metastasis and osteoporosis in lung cancer. International Journal of Pharmacology, 2018. 14(4): p. 471-476.	Geen full-text
Xu, G., Z. Zeng, and W. Fan Randomised comparative clinical trial of treatment of bone metastases of head and neck carcinoma by clodronate and 153 SmEDTMP. Chinese journal of cancer, 1999.	Geen full-text
Yan, T., et al., The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. European Journal of Cancer, 2012. 48(2): p. 187-95.	Geen botmetastasen
Yang, L. and S. Du, Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis. Medicine, 2015. 94(42): p. e1822.	Geen kwaliteitsbeoordeling van geïncludeerde studies
Yang, M. and X. Yu, Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency. Supportive Care in Cancer, 2020. 28(6): p. 2533-2540.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Yavux, M., et al. Effects of pamidronate use on the palliative radiotherapy of bone metastases: a prospective randomized study. International journal of radiation oncology biology physics, 2000. 48, 185-186.	Abstract
Yuen, K.Y., et al., Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews, 2006(4).	Updated
Zaghloul, M.S., et al., A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. International Journal of Clinical Oncology, 2010. 15(4): p. 382-9.	Hypercalciëmie niet gerapporteerd, wel SREs
Zhang, G., et al. Phase II randomized clinical trial of zoledronic acid in treating metastatic bone pain of malignancy. Ai zheng [Chinese journal of cancer], 2005. 24, 1489-1492.	Chinees
Zhang, G., H. Gong, and H. Xu Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases. Computational and mathematical methods in medicine, 2021. 2021, 5343104 DOI: 10.1155/2021/5343104.	Geen kwantitatieve data over calcium
Zhang, L., Z. Guan, and Y. He Randomised comparative clinical trial of treatment of bone metastatic diseases by infusion of palidronate and clodronate. Chinese journal of cancer, 1997. 16, 430-432.	Geen full-text
Zhang, X., et al. Influence of bisphosphonate combined with chemotherapy on bone mineral density of patients with multiple myeloma. Zhongguo shi yan xue ye xue za zhi [Journal of experimental hematology], 2012. 20, 1135-1138.	Chinees
Zhang, X., et al., The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients. Hematology, 2012. 17(5): p. 255-60.	Serum Ca, geen %

Zhang, Z., F. Pu, and Z. Shao, The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials. <i>Journal of Bone Oncology</i> , 2017. 9: p. 21-24.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Zhao, Y.Y., et al., Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. <i>European Journal of Cancer</i> , 2011. 47(6): p. 848-53.	Hypercalciëmie niet gerapporteerd, wel SREs en safety
Zheng, G.Z., et al., Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. <i>European Journal of Cancer Care</i> , 2017. 26(6).	Hypercalciëmie niet gerapporteerd, wel SREs
Zhu, M., et al., Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials. <i>Pain Medicine</i> , 2013. 14(2): p. 257-64.	Hypercalciëmie niet gerapporteerd, wel SREs en safety

Bijlage GRADE profielen  
(per onderzoeksvraag op te stellen; export vanuit GRADEpro)